预防方案降低分支/开窗腔内主动脉修复患者的脊髓缺血
该研究在佛罗里达大学和阿拉巴马大学伯明翰分校两中心比较了2015年5月常规实施集束化脊髓缺血预防方案前后的分支/开窗腔内主动脉修复患者,方案后组402例、方案前组160例,脊髓缺血发生率由15.9%降至3.0%(P < .001),高危患者由23.2%降至5.0%(P < .001),30天死亡率由6.3%降至2.2%(P = .02)。
要点
- 集束化脊髓缺血预防方案实施后,分支/开窗腔内主动脉修复患者脊髓缺血发生率由15.9%降至3.0%(P < .001)。
- 高危患者中方案前组脊髓缺血发生率为23.2%,方案后组为5.0%(P < .001)。
- 30天死亡率方案前组6.3% vs 方案后组2.2%(P = .02),1年生存率84.4% vs 88.3%(log-rank P = .35)无显著差异。
核心结论
- 实施集束化脊髓缺血预防方案可显著降低分支/开窗腔内主动脉修复患者的脊髓缺血发生率,并已在两个中心得到验证,高危患者中降幅最显著。
- 两队列总体1年死亡率差异无统计学显著意义,但脊髓缺血患者死亡率高,突显预防措施的重要性。
研究设计与样本
- 单中心研究此前已报告集束化脊髓缺血预防方案较历史队列降低脊髓缺血发生率,本研究在佛罗里达大学和阿拉巴马大学伯明翰分校两个中心进一步验证并更新该方案常规实施后的结局。
- 方案后队列为2015年5月至2022年12月接受分支/开窗腔内主动脉修复的患者(n = 402),方案前队列为2010年1月至2015年4月的患者(n = 160)。
- 该方案于2015年5月常规实施,内容包括选择性脑脊液引流、规定的血压参数、输血目标及选择性药物辅助(纳洛酮、类固醇)。
- 主要结局为脊髓缺血发生率,并对高危患者(Crawford I-III型胸腹主动脉瘤夹层相关疾病、既往主动脉修复、覆盖近端至5区)进行亚组分析;生存分析采用Kaplan-Meier法。
主要发现
- 两队列人口学相似,但方案后组美国麻醉医师学会IV级患者更多(86.1% vs 55.0%;P < .001)。
- 胸腹主动脉瘤为两组最常见的手术指征。
- 方案后组脑脊液引流放置更常见,尤其在高危患者中。
- 脊髓缺血发生率方案前组为15.9%,方案后组为3.0%(P < .001)。
- 高危患者中脊髓缺血发生率方案前组为23.2%,方案后组为5.0%(P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Spinal cord ischemia (SCI) is a devastating complication that is associated with thoracoabdominal aortic repair, with higher risk associated with increased aortic coverage length, making patients undergoing branched/fenestrated endovascular repair (B/FEVAR) particularly vulnerable. A bundled SCI prevention protocol was previously reported to reduce SCI rates when compared to a historic cohort in a single-center study. Therefore, this analysis aims to further validate and update outcomes associated with the protocol given the routine implementation of this strategy at two institutions (University of Florida and the University of Alabama at Birmingham) since inception. METHODS: Components of the SCI prevention protocol include selective cerebrospinal fluid drainage, specified blood pressure parameters, transfusion goals, and selective pharmacologic adjuncts (naloxone, steroids). This protocol was routinely implemented in May 2015. Patients undergoing B/FEVAR from May 2015 to December 2022 constituted the post-protocol cohort (n = 402) and were compared with the pre-protocol cohort (n = 160; January 2010-April 2015). The primary outcome was SCI incidence, and subgroup analysis was conducted among patients deemed to be high-risk (Crawford extent I-III thoracoabdominal aneurysm dissection-related disease, prior aortic repair, coverage proximal to zone 5). Survival analysis was performed using Kaplan-Meier methodology. RESULTS: The pre- and post-protocol cohorts were demographically similar, although more post-protocol patients were American Society of Anesthesiology class IV (86.1% vs 55.0%; P < .001). Thoracoabdominal aneurysm was the most common indication in both groups. Cerebrospinal fluid drain placement was more common in the post-protocol group, particularly among high-risk patients. SCI occurred in 15.9% of pre-protocol patients vs 3.0% of post-protocol patients (P < .001). In high-risk patients, the pre- and post-protocol cohort SCI incidence was 23.2% vs 5.0%, respectively (P < .001). Thirty-day mortality was decreased in the post-protocol cohort (6.3% vs 2.2%; P = .02). Although the post-protocol group had a trend toward improved 1-year survival, this was not statistically significant (84.4% vs 88.3%; log-rank P = .35). Among patients with SCI, 1-year mortality was 28% and 33.3% in the pre- and post-protocol groups, respectively (P = .46). CONCLUSIONS: Implementation of a bundled SCI prevention protocol significantly reduces SCI rates in patients undergoing B/FEVAR, which has now been validated at two institutions, with the most significant reductions occurring among high-risk patients. Although the overall 1-year mortality difference was not significantly different between the cohorts, the high mortality rates among patients with SCI highlights the importance of preventative measures.
引用
- Sickels AD, Novak Z, Scali ST, et al. A prevention protocol reduces spinal cord ischemia in patients undergoing branched/fenestrated endovascular aortic repair. J Vasc Surg. 2024. PMID: 39222828. doi:10.1016/j.jvs.2024.08.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。